2XA Stock Overview
Operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
BenevolentAI S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.70 |
| 52 Week High | €0.83 |
| 52 Week Low | €0.42 |
| Beta | 0.89 |
| 11 Month Change | -5.95% |
| 3 Month Change | 27.01% |
| 1 Year Change | 22.11% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2XA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -1.0% | 0.2% |
| 1Y | 22.1% | -19.3% | 8.5% |
Return vs Industry: 2XA exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 2XA exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 2XA volatility | |
|---|---|
| 2XA Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 2XA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2XA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 180 | n/a | www.benevolent.com |
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company’s development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson’s disease.
BenevolentAI S.A. Fundamentals Summary
| 2XA fundamental statistics | |
|---|---|
| Market cap | €89.02m |
| Earnings (TTM) | -€61.56m |
| Revenue (TTM) | €5.83m |
15.3x
P/S Ratio-1.4x
P/E RatioIs 2XA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2XA income statement (TTM) | |
|---|---|
| Revenue | UK£4.87m |
| Cost of Revenue | UK£2.79m |
| Gross Profit | UK£2.08m |
| Other Expenses | UK£53.49m |
| Earnings | -UK£51.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 42.77% |
| Net Profit Margin | -1,056.02% |
| Debt/Equity Ratio | 0% |
How did 2XA perform over the long term?
See historical performance and comparison